Related Experiment Video
Updated: Jun 13, 2025
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
Identification of shared pathophysiological molecules of major psychiatric disorders: A comprehensive analysis of
Yuki Jimbayashi Kutsuna1, Nozomi Aibara2, Junya Hashizume3
1Department of Molecular Pathochemistry, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Recent studies indicate common inflammatory findings have been identified in peripheral blood in patients with major psychiatric disorders, including schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD). Electroconvulsive therapy (ECT) frequently improves both severe symptoms and inflammatory markers in these conditions. However, the shared inflammatory mechanisms underlying these disorders, and thus, reliable biomarkers remain unclear. We hypothesized that the activation of immune complexes (ICs) contributes to inflammatory pathogenesis of these disorders. Using immune complexome analysis, we examined antigens forming ICs (IC-antigens) in the serum of patients with SCZ, BD, and MDD (n = 60) before and after ECT. Our analysis showed that although the overall quantity of ICs did not change before and after ECT, four proteins significantly decreased following ECT. These proteins were DENN domain-containing protein 1C (DENND1C), double-stranded RNA-specific editase 1 (ADARB1), perilipin-4, and coagulation factor XI, which were all consistently detected as IC-antigens across patient groups. Notably, DENND1C, ADARB1, and perilipin-4 were specific to psychiatric patients and absent in healthy controls. The abundance of these IC-antigens significantly correlated with psychiatric symptom scores, with DENND1C showing a particularly strong correlation with total symptom scores across all three disorders. These findings suggest that DENND1C may contribute to the shared pathophysiology of SCZ, BD, and MDD through antigenization or IC formation. This highlights its potential as a biomarker for ECT treatment availability and diagnostic/treatment efficacy monitoring.
Recent studies indicate common inflammatory findings have been identified in peripheral blood in patients with major psychiatric disorders, including schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD). Electroconvulsive therapy (ECT) frequently improves both severe symptoms and inflammatory markers in these conditions. However, the shared inflammatory mechanisms underlying these disorders, and thus, reliable biomarkers remain unclear. We hypothesized that the activation of immune complexes (ICs) contributes to inflammatory pathogenesis of these disorders. Using immune complexome analysis, we examined antigens forming ICs (IC-antigens) in the serum of patients with SCZ, BD, and MDD (n = 60) before and after ECT. Our analysis showed that although the overall quantity of ICs did not change before and after ECT, four proteins significantly decreased following ECT. These proteins were DENN domain-containing protein 1C (DENND1C), double-stranded RNA-specific editase 1 (ADARB1), perilipin-4, and coagulation factor XI, which were all consistently detected as IC-antigens across patient groups. Notably, DENND1C, ADARB1, and perilipin-4 were specific to psychiatric patients and absent in healthy controls. The abundance of these IC-antigens significantly correlated with psychiatric symptom scores, with DENND1C showing a particularly strong correlation with total symptom scores across all three disorders. These findings suggest that DENND1C may contribute to the shared pathophysiology of SCZ, BD, and MDD through antigenization or IC formation. This highlights its potential as a biomarker for ECT treatment availability and diagnostic/treatment efficacy monitoring.
More Related Videos
11:31Rapid Fractionation and Isolation of Whole Blood Components in Samples Obtained from a Community-based Setting
Published on: November 30, 2015
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
